Arachnoid Cysts Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the arachnoid cysts treatment market size is projected to expand from USD 1.8 billion in 2025 and USD 1.9 billion in 2026 to USD 2.5 billion by 2031, registering a CAGR of 5.59% between 2026 to 2031.

This report is Segmented by Type (Intracranial Arachnoid Cysts, and More), Treatment Type (Endoscopic Cyst Fenestration, Microsurgical Fenestration, Cystoperitoneal Shunting, and More), End-User (Hospitals, Ambulatory Surgical Centers, and More), and Geography (North America, South America, Europe, APAC, Middle East, and Africa). Market Forecasts are Provided in Terms of Value (USD).

Global Arachnoid Cysts Treatment Market Trends and Insights

Advances in Minimally Invasive Neuroendoscopy Drive Procedural Shift

Neuroendoscopic fenestration now anchors first-line therapy, propelled by FDA clearances for systems that pair 4 mm rigid scopes with near-infrared fluorescence to map subsurface vessels and avert venous injury. Integra's single-use AURORA Surgiscope, cleared in April 2025, folds LED lighting and video into a sterile sheath, cutting reprocessing time and infection exposure . A 2024 meta-analysis reported 75% radiographic cyst reduction and 90% headache relief after posterior fossa decompression, reinforcing confidence in endoscopy. Recurrence persists at 10-30%, steering R&D toward biodegradable stents that prop open fenestrations. Shorter average hospitalization of 1.5 days now aligns fenestration economics with ambulatory surgical center models.

Expanding Pediatric Neurosurgery Infrastructure Unlocks Emerging-Market Demand

Government-funded hybrid suites in India, China, and Southeast Asia are broadening operative capacity. Tamil Nadu's integrated theatre, inaugurated in November 2025, merges CT, endoscopy, and ultrasound, enabling 40-50 complex cases per month and eliminating risky mid-procedure transfers. Argentina's neurosurgery society embedded a 720-hour pediatric curriculum that includes arachnoid cyst techniques, signaling talent pipeline expansion. Telemedicine corridors linking Pakistan with Beijing Tiantan Hospital streamline pre-op triage and reserve cross-border referrals for the toughest lesions, trimming travel costs and accelerating care.

High Procedural Costs and Reimbursement Complexity Limit Access

Endoscopic fenestration CPT codes (e.g., 62161) often require prior authorization in the U.S., delaying therapy for most patients and tightening hospital cash flows . In many emerging economies, out-of-pocket bills between USD 3,000 and USD 5,000 keep surgery out of reach. Bundling of navigation and imaging add-on codes further clouds revenue predictability. Pediatric families without insurance frequently defer care until hydrocephalus sets in, crimping the immediately addressable portion of the arachnoid cysts treatment market.

Other drivers and restraints analyzed in the detailed report include:

1. Improved High-Resolution MRI Expands Diagnostic Capture of Symptomatic Cases
2. Growing Adoption of Programmable Shunt Valves Reduces Overdrainage Complications
3. Surgical Complication Risks and Recurrence Rates Constrain Adoption

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Intracranial cysts commanded 78.19% of the arachnoid cysts treatment market in 2025, mainly because middle cranial fossa and retrocerebellar locations provoke headaches, seizures, or hydrocephalus that necessitate surgery. Galassi type III lesions usually bypass observation and move straight to fenestration or shunting. Spinal arachnoid cysts hold a sliver of current revenue yet are forecast at a robust 7.30% CAGR as safer laminectomy protocols extend operability.

The arachnoid cysts treatment market size attributable to intracranial surgery is projected to widen steadily through 2031, while spinal cases benefit from neuromonitoring that curbs cord-injury risk. Although spinal cysts lack a universal classification scheme, thoracic lesions that compress the dorsal columns are moving toward earlier excision, increasing the demand for low-profile retractors. Combined, these dynamics keep intracranial volume high and spinal growth brisk, sustaining product line diversification for device makers.

Geography Analysis

North America generated 47.17% of 2025 revenue. Widespread insurance coverage and dense neurosurgeon networks buoy procedure volumes, although prior authorization delays continue to blur scheduling. Canada's single-payer model ensures universal access but prolongs elective waitlists. Mexico's private centers draw uninsured U.S. patients with package prices that undercut domestic quotes, nudging tourism inflows and adding a niche layer to the arachnoid cysts treatment market.

Asia-Pacific is projected to climb at 7.45% CAGR through 2031. India's first government-run hybrid neurosurgery suite demonstrates how public capital can pivot regional surgical capacity upward. China's flagship hospitals blend intraoperative CT and neuronavigation, while telemedicine links extend consult reach into Pakistan and Bangladesh. Southeast Asian growth rides pediatric demand spikes and multi-lateral training partnerships. Japan and South Korea hover near saturation, but their aging installed base will demand replacement endoscopes and valves.

Europe remains steady, its universal health systems undergirding consistent procedure counts. Germany and the United Kingdom steer volumes, with the NHS favoring conservative follow-up for asymptomatic cysts. Eastern European states are investing in hybrid theatres to stem outbound medical migration. South America is gradually assembling pediatric neurosurgery muscle, led by Brazil and Argentina, though reimbursement gaps still limit cross-border device adoption, moderating the regional share of the arachnoid cysts treatment market.

1. Abbott Laboratories
2. Aesculap, Inc
3. B. Braun
4. Boston Scientific
5. Brain Lab
6. Conmed
7. GE Healthcare
8. Integra LifeSciences
9. Karl Storz
10. Danaher
11. Medtronic
12. Miethke (Christoph Miethke GmbH)
13. Natus Medical
14. Nihon Kohden
15. Olympus
16. Penumbra
17. Koninklijke Philips
18. Siemens Healthineers
19. Sophysa
20. Stryker
21. Zeiss

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support